A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity, m-AMSA has little activity in patients with gastric adenocarcinoma.
|Original language||English (US)|
|Number of pages||3|
|Journal||American Journal of Clinical Oncology: Cancer Clinical Trials|
|Publication status||Published - Dec 1 1982|
ASJC Scopus subject areas
- Cancer Research